Global Liver Cirrhosis Therapeutics Market 2016-2020

2016-05-06
Price :
Published : May-2016
No. of Pages : 74

Cirrhosis of the liver (or liver fibrosis) is a serious condition in which the liver stops functioning properly due to damage and irreversible scarring of the liver tissue. The scarring of the tissue is often caused by long-term exposure to viral infections and toxins such as alcohol. Chronic viral hepatitis and non-alcoholic steatohepatitis can also cause liver cirrhosis. Alcohol-related medications, antiviral medications, and metal chelating agents are used in the treatment of the causes of liver cirrhosis while antibiotics, vitamins, corticosteroids, diuretics, beta-blockers, and laxatives are used for the treatment of the complications of the disease.

The analysts forecast global liver cirrhosis therapeutics market to grow at a CAGR of 4.36% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global liver cirrhosis therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of liver cirrhosis.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

The report, Global Liver Cirrhosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F Hoffman La-Roche
  • GlaxoSmithKline
  • Gilead Sciences
  • Johnson & Johnson
  • Merck

Other prominent vendors

  • Bristol-Myers Squibb
  • Conatus Pharmaceuticals
  • Gwo Xi Stem Cell Applied Technology
  • Instituto Grifols
  • Intercept Pharmaceuticals
  • NGM Biopharmaceuticals
  • Norgine
  • Pharmicell
  • Salix Pharmaceuticals
  • Stempeutics Research

Market driver

  • High prevalence of liver cirrhosis
  • For a full, detailed list, view our report

Market challenge

  • Adverse effects of drugs
  • For a full, detailed list, view our report

Market trend

  • Use of off-label drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical, Therapeutics
Publisher : Technavio
More Reports
Title Price Buy Now

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Venezuela

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Venezuela Summary Venezuela ranked 187 out of 190 countries in ease of doing business. In July 2017, rating firm Standard & Poor's downgraded Venezuela's economy to CCC with a negative outlook. Moody's also downgraded its rating to Caa3 with a negative outlook, while Fitch rated it at CCC with a negative outlook. Venezuela is one of the emerging pharmaceutical markets in South America, with a major dependence on imports. However, economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers. The value of the market was US$12.6 Billion in 2015, having increased from US$5.7 Billion in 2009, at a Compound Annual Growth Rate (CAGR) of 14.1%. Drug prices in Venezuela are ......
$1995

Hemorrhagic Shock Global Clinical Trials Review, H2, 2017

Hemorrhagic Shock Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemorrhagic Shock Global Clinical Trials Review, H2, 2017" provides an overview of Hemorrhagic Shock clinical trials scenario. This report provides top line data relating to the clinical trials on Hemorrhagic Shock. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trial......
$2500

Hepatitis E Global Clinical Trials Review, H2, 2017

Hepatitis E Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatitis E Global Clinical Trials Review, H2, 2017" provides an overview of Hepatitis E clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis E. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Hemorrhoids Global Clinical Trials Review, H2, 2017

Hemorrhoids Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemorrhoids Global Clinical Trials Review, H2, 2017" provides an overview of Hemorrhoids clinical trials scenario. This report provides top line data relating to the clinical trials on Hemorrhoids. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Hepatobiliary Disease Global Clinical Trials Review, H2, 2017

Hepatobiliary Disease Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatobiliary Disease Global Clinical Trials Review, H2, 2017" provides an overview of Hepatobiliary Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatobiliary Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500

Hemostasis Global Clinical Trials Review, H2, 2017

Hemostasis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemostasis Global Clinical Trials Review, H2, 2017" provides an overview of Hemostasis clinical trials scenario. This report provides top line data relating to the clinical trials on Hemostasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017

Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatocellular Carcinoma Global Clinical Trials Review, H2, 2017" provides an overview of Hepatocellular Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500

Hemochromatosis Global Clinical Trials Review, H2, 2017

Hemochromatosis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemochromatosis Global Clinical Trials Review, H2, 2017" provides an overview of Hemochromatosis clinical trials scenario. This report provides top line data relating to the clinical trials on Hemochromatosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials databa......
$2500

Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017

Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatic Encephalopathy Global Clinical Trials Review, H2, 2017" provides an overview of Hepatic Encephalopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatic Encephalopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma e......
$2500

Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017

Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hepatorenal Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Hepatorenal Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatorenal Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Cl......
$2500